CM
AVDL

Crestline Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Crestline Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,637
Closed -$192K – 721
2024
Q3 		$192K Buy
+14,637
New +$223K 0.01% 504

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Crestline Management's AVDL Position: Q4 2024 in Review

Crestline Management sold out of Avadel Pharmaceuticals (AVDL) in Q4 2024, closing a stake of 14,637 shares — an estimated $192K sold.

Crestline Management first reported a position in AVDL in Q3 2024 and held it in 1 quarter. The position peaked at $192K in Q3 2024. 159 funds tracked by Wall St. Rank hold AVDL as of Q4 2024.

  • Crestline Management reported no remaining Avadel Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Crestline Management sold 14,637 Avadel Pharmaceuticals shares in Q4 2024, an estimated $192K.
  • Crestline Management first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Crestline Management's Avadel Pharmaceuticals position peaked at $192K in Q3 2024.
  • 159 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2024.

Based on Crestline Management's 13F filing for Q4 2024, filed 14 Feb 2025.